Wikimedia CommonsBefore the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company is expected to post earnings per share (EPS) of $0.52 on revenues of $11.42…
ThinkstockMerck & Co. Inc. (NYSE: MRK) reports on Tuesday morning comes into earnings with shares up only 2.7% or so year to date, and up only about 1.7% from a year ago. Thomson Reuters…
ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct to diet and maximally…
ThinkstockTeladoc Inc. (NYSE: TDOC) was a hot initial public offering this summer, and shares remain 50% higher than at the time of the IPO. The company sold some 8,250,000 shares of common stock at…
ThinkstockAimmune Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering. The expected price range was set as $14 to $16 for 8.33 million shares with…
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials. There is…
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them.…
In a deal which had been anticipated, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would buy Allergan Generics in a transaction valued at $40.5 billion. According to a press release issued by the two…
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK) and Pfizer…
Sunesis Pharmaceuticals probably wishes that this Friday never happened, as shares were down almost 70% just after the opening bell.
AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.
Biogen reported mixed second-quarter 2015 results before markets opened Friday morning.
Biogen is scheduled to release its second-quarter financial results before the markets open on Friday.
Cara Therapeutics may not be a household name, but its shares scream higher on Thursday after clearing Phase 2 trial data.
Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.